Table 5. Other Outcomes of the Trial.
| Outcome | Group, No. (%) | Unadjusted | Adjusted | |||
|---|---|---|---|---|---|---|
| Magnesium (n = 409) | Placebo (n = 407) | Risk difference (95% CI) | P value | Risk difference (95% CI)a | P value | |
| Hospitalization within 72 h | 180 (44.01) | 196 (48.16) | −0.04 (−0.11 to 0.03) | .23 | −0.05 (−0.10 to 0.02) | .19 |
| Revisit to any medical facility within 72 h | 21/236 (8.90) | 15/215 (6.98) | 0.02 (−0.03 to 0.07) | .45 | 0.02 (−0.07 to 5.57) | .54 |
| Intravenous magnesium in emergency departmentb | 100 (24.45) | 115 (28.26) | −0.04 (−0.10 to 0.02) | .22 | −0.04 (−0.09 to 0.02) | .19 |
a
Post hoc adjustment was made for stratification at randomization for age group, with site as a random effect.
b
Intravenous magnesium was administered after the experimental therapy.